
Robert R. Niquette
Examiner (ID: 16297, Phone: (571)270-3613 , Office: P/3696 )
| Most Active Art Unit | 3696 |
| Art Unit(s) | 3695, 3691, 3696, 3699 |
| Total Applications | 795 |
| Issued Applications | 463 |
| Pending Applications | 51 |
| Abandoned Applications | 293 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20419200
[patent_doc_number] => 20250381285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-12-18
[patent_title] => COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 19/263325
[patent_app_country] => US
[patent_app_date] => 2025-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19263325
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/263325 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Jul 7, 2025 | Pending |
Array
(
[id] => 20321455
[patent_doc_number] => 20250333543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-30
[patent_title] => FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 19/256452
[patent_app_country] => US
[patent_app_date] => 2025-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19256452
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/256452 | FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE | Jun 30, 2025 | Pending |
| 19/234136 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | Jun 9, 2025 | Pending |
Array
(
[id] => 20163936
[patent_doc_number] => 20250255982
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-14
[patent_title] => ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 19/098785
[patent_app_country] => US
[patent_app_date] => 2025-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35063
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19098785
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/098785 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | Apr 1, 2025 | Pending |
Array
(
[id] => 20099021
[patent_doc_number] => 20250228957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS
[patent_app_type] => utility
[patent_app_number] => 19/060384
[patent_app_country] => US
[patent_app_date] => 2025-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26868
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19060384
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/060384 | BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS | Feb 20, 2025 | Pending |
Array
(
[id] => 20033323
[patent_doc_number] => 20250171545
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-29
[patent_title] => N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 19/035322
[patent_app_country] => US
[patent_app_date] => 2025-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19848
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19035322
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/035322 | N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES | Jan 22, 2025 | Pending |
Array
(
[id] => 20016005
[patent_doc_number] => 20250154227
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-15
[patent_title] => ALBUMIN PROTEIN VARIANTS, PRODUCTION THEREOF AND USES OF SAME
[patent_app_type] => utility
[patent_app_number] => 19/023442
[patent_app_country] => US
[patent_app_date] => 2025-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19023442
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/023442 | ALBUMIN PROTEIN VARIANTS, PRODUCTION THEREOF AND USES OF SAME | Jan 15, 2025 | Pending |
Array
(
[id] => 20068625
[patent_doc_number] => 20250206847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-26
[patent_title] => DIMERIC ANTIBODIES AND THEIR METHODS OF MANUFACTURE
[patent_app_type] => utility
[patent_app_number] => 19/002112
[patent_app_country] => US
[patent_app_date] => 2024-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11726
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 311
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19002112
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/002112 | DIMERIC ANTIBODIES AND THEIR METHODS OF MANUFACTURE | Dec 25, 2024 | Pending |
Array
(
[id] => 19876951
[patent_doc_number] => 20250109208
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-03
[patent_title] => Antibodies Targeting ActRIIA and ActRIIB
[patent_app_type] => utility
[patent_app_number] => 18/945784
[patent_app_country] => US
[patent_app_date] => 2024-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18945784
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/945784 | Antibodies targeting ActRIIA and ActRIIB | Nov 12, 2024 | Issued |
Array
(
[id] => 19916225
[patent_doc_number] => 12291579
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-06
[patent_title] => Anti-phosphocholine antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/920412
[patent_app_country] => US
[patent_app_date] => 2024-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38677
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18920412
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/920412 | Anti-phosphocholine antibodies and methods of use thereof | Oct 17, 2024 | Issued |
Array
(
[id] => 19830984
[patent_doc_number] => 20250082770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-13
[patent_title] => ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING CARCINOEMBYRONIC ANTIGEN
[patent_app_type] => utility
[patent_app_number] => 18/892256
[patent_app_country] => US
[patent_app_date] => 2024-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31492
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18892256
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/892256 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING CARCINOEMBYRONIC ANTIGEN | Sep 19, 2024 | Pending |
Array
(
[id] => 19477511
[patent_doc_number] => 20240325553
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS
[patent_app_type] => utility
[patent_app_number] => 18/744084
[patent_app_country] => US
[patent_app_date] => 2024-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10082
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18744084
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/744084 | CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS | Jun 13, 2024 | Abandoned |
Array
(
[id] => 19657060
[patent_doc_number] => 20240424125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/677564
[patent_app_country] => US
[patent_app_date] => 2024-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18677564
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/677564 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | May 28, 2024 | Issued |
Array
(
[id] => 19526746
[patent_doc_number] => 20240350648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => INTRACELLULAR DELIVERY COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/653316
[patent_app_country] => US
[patent_app_date] => 2024-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653316
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/653316 | INTRACELLULAR DELIVERY COMPOSITIONS | May 1, 2024 | Pending |
Array
(
[id] => 19586450
[patent_doc_number] => 20240384007
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION
[patent_app_type] => utility
[patent_app_number] => 18/629314
[patent_app_country] => US
[patent_app_date] => 2024-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 145061
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629314
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/629314 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | Apr 7, 2024 | Pending |
Array
(
[id] => 19512116
[patent_doc_number] => 20240343802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
[patent_app_type] => utility
[patent_app_number] => 18/612960
[patent_app_country] => US
[patent_app_date] => 2024-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612960
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | Mar 20, 2024 | Pending |
Array
(
[id] => 20173037
[patent_doc_number] => 12391770
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-19
[patent_title] => Compositions and methods comprising antibodies that bind to covalent peptide conjugates
[patent_app_type] => utility
[patent_app_number] => 18/585676
[patent_app_country] => US
[patent_app_date] => 2024-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 24
[patent_no_of_words] => 12670
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 228
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18585676
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/585676 | Compositions and methods comprising antibodies that bind to covalent peptide conjugates | Feb 22, 2024 | Issued |
Array
(
[id] => 19784177
[patent_doc_number] => 20250057856
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 18/443821
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443821
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443821 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Feb 15, 2024 | Pending |
Array
(
[id] => 19380976
[patent_doc_number] => 20240270846
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION BINDING CD3 AND CD137
[patent_app_type] => utility
[patent_app_number] => 18/436917
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72525
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436917
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436917 | ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION BINDING CD3 AND CD137 | Feb 7, 2024 | Pending |
Array
(
[id] => 19282905
[patent_doc_number] => 20240219381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN
[patent_app_type] => utility
[patent_app_number] => 18/430887
[patent_app_country] => US
[patent_app_date] => 2024-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27524
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 325
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430887
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/430887 | METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN | Feb 1, 2024 | Pending |